269 related articles for article (PubMed ID: 2302870)
1. Pharmacokinetics and pharmacodynamics of subcutaneous and intraperitoneal administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
Lui SF; Chung WW; Leung CB; Chan K; Lai KN
Clin Nephrol; 1990 Jan; 33(1):47-51. PubMed ID: 2302870
[TBL] [Abstract][Full Text] [Related]
2. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
Lui SF; Law CB; Ting SM; Li P; Lai KN
Clin Nephrol; 1991 Nov; 36(5):246-51. PubMed ID: 1752075
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of recombinant erythropoietin after subcutaneous or intraperitoneal administration to patients on CAPD.
Icardi A; Paoletti E; Molinelli G
Adv Perit Dial; 1990; 6():292-5. PubMed ID: 1982830
[TBL] [Abstract][Full Text] [Related]
4. Treatment of the anemia with human recombinant erythropoietin in CAPD patients.
Miranda B; Selgas R; Riñon C; Fernandez-Zamorano A; Borrego F; Ortuño F; Lopez-Revuelta K; Torre A; Sanchez Sicilia L
Adv Perit Dial; 1990; 6():296-301. PubMed ID: 1982831
[TBL] [Abstract][Full Text] [Related]
5. Correction of anemia in patients on continuous ambulatory peritoneal dialysis with subcutaneous recombinant erythropoietin twice a week: a long-term study.
Cheng IK; Cy C; Chan MK; Yu L; Fang GX; Wei D
Clin Nephrol; 1991 May; 35(5):207-12. PubMed ID: 1855328
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous recombinant human erythropoietin in patients on CAPD.
Lye WC; Lee EJ
Adv Perit Dial; 1991; 7():285-7. PubMed ID: 1680447
[TBL] [Abstract][Full Text] [Related]
7. Use of bolus intraperitoneal iron dextran in continuous ambulatory peritoneal dialysis or continuous cyclic peritoneal dialysis patients receiving recombinant human erythropoietin.
Mars RL; Moles K; Pope K; Hargrove P
Adv Perit Dial; 1999; 15():60-4. PubMed ID: 10682073
[TBL] [Abstract][Full Text] [Related]
8. Anemia of chronic renal failure: treatment with erythropoietin.
Navarro M; Alonso A; Avilla JM; Espinosa L
Child Nephrol Urol; 1991; 11(3):146-51. PubMed ID: 1777893
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic studies on recombinant human erythropoietin.
Salmonson T
Scand J Urol Nephrol Suppl; 1990; 129():1-66. PubMed ID: 2255869
[TBL] [Abstract][Full Text] [Related]
10. Intraperitoneal erythropoietin in children on peritoneal dialysis: A study of pharmacokinetics and efficacy.
Kausz AT; Watkins SL; Hansen C; Godwin DA; Palmer RB; Brandt JR
Am J Kidney Dis; 1999 Oct; 34(4):651-6. PubMed ID: 10516345
[TBL] [Abstract][Full Text] [Related]
11. One year experience with subcutaneous human erythropoietin in CAPD: correction of renal anemia and increased ultrafiltration.
Lubrich-Birkner I; Schollmeyer P; Steinhauer HB
Adv Perit Dial; 1990; 6():302-7. PubMed ID: 1982833
[TBL] [Abstract][Full Text] [Related]
12. Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysis.
Lai KN; Lui SF; Leung JC; Law E; Nicholls MG
Nephron; 1991; 57(4):394-400. PubMed ID: 1828543
[TBL] [Abstract][Full Text] [Related]
13. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
[TBL] [Abstract][Full Text] [Related]
14. rHuEPO in the treatment of postpartum anemia: subcutaneous versus intravenous administration.
Zimmermann R; Breymann C; Huch R; Huch A
Clin Investig; 1994; 72(6 Suppl):S25-30. PubMed ID: 7950168
[TBL] [Abstract][Full Text] [Related]
15. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease.
Macdougall IC; Robson R; Opatrna S; Liogier X; Pannier A; Jordan P; Dougherty FC; Reigner B
Clin J Am Soc Nephrol; 2006 Nov; 1(6):1211-5. PubMed ID: 17699350
[TBL] [Abstract][Full Text] [Related]
17. Intravenous versus subcutaneous administration of recombinant human erythropoietin in patients on haemodialysis and CAPD.
Eidemak I; Friedberg MO; Ladefoged SD; Løkkegaard H; Pedersen E; Skielboe M
Nephrol Dial Transplant; 1992; 7(6):526-9. PubMed ID: 1320232
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic study of recombinant human erythropoietin treatment in pre-dialysis end stage renal disease patients.
Yamazaki C; Watanabe Y; Sakamoto N
Nihon Jinzo Gakkai Shi; 1993 Nov; 35(11):1233-42. PubMed ID: 8139135
[TBL] [Abstract][Full Text] [Related]
19. Comparison of intramuscular versus subcutaneous erythropoietin for the treatment of anemia in CAPD patients.
Abreo K; Lubom JA; Collier L; Fleming D; Work J
Adv Perit Dial; 1994; 10():124-8. PubMed ID: 7999809
[TBL] [Abstract][Full Text] [Related]
20. Comparative effects of erythropoietin with oral iron in peritoneal dialysis and hemodialysis patients.
Raja R; Bloom E; Johnson R
Adv Perit Dial; 1993; 9():177-80. PubMed ID: 8105918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
